Jump to content

All Activity

This stream auto-updates     

  1. Yesterday
  2. Emperor G_D

    SR9011?

    I was pretty sure I had posted a helpful pdf some time back with a whole collection of exercise mimetics and like substances. ~~~ REV-ERBa Ligands Other in vivo-tested exercise mimetics include SR9009 and SR9011, synthetic ligands of REV-ERBa, a nuclear receptor that plays a critical role in regulating circadian rhythm and energy metabolism. When activated by these compounds, REV-ERBa recruits co-repressors such as SMRT and NCOR1 and suppresses the expression of its target genes. Most metabolic genes in muscle are circadian, and thus the relative amplitudes of these circuits are REV-ERB dependent (Zhao et al., 2016). In muscle, REV-ERBa is selectively expressed in oxidative myofibers and is further induced by exercise. Its overexpression in muscle increases mitochondrial biogenesis and fatty acid metabolism, while its ablation results in the reverse effects. REV-ERBa does not directly regulate mitochondrial genes but rather may induce their expression indirectly through the AMPK-SIRT1-PGC1a pathway (Canto´ et al., 2010), though the mechanism remains unclear. This action makes REV-ERBa an ideal candidate for the development of exercise mimetics. Indeed, in vivo SR9009 or SR9011 treatment mimics exercise by inducing mitochondrial biogenesis as well as fatty acid oxidation, and improves endurance performance (Woldt et al., 2013). ~~~ TBH, I assume most things on the market are tainted, or bullshit, or dangerous, and maybe it's just me being in my 40s, but I don't do much experimentation with RCs anymore. Please run it and report back...I'd be happy to run it if it were safe and effective. More often than not I wonder how much something would cost me to import and have assayed, and then when I realize that it would cost like 4 billion dollars, I wander off and find something else that is shiny to look at.
  3. Mine will be arriving today, too. I went with the linked formula above. It's straight 3,5-T2 with no 3,3. 100mcg per dose. We'll see if fasting+T2 helps my fat loss along any.
  4. Looks like Victoza might be covered for me. Good timing.
  5. Related drug, liraglutide is indicated for obesity, specifically coincident with HTN.
  6. J Manag Care Spec Pharm. 2018 Sep;24(9-a Suppl):S14-S29. doi: 10.18553/jmcp.2018.24.9-a.s14. Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists. Handelsman Y1, Wyne K2, Cannon A3, Shannon M4, Schneider D5. Abstract This article provides an overview of the efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the treatment of type 2 diabetes mellitus (T2DM). GLP-1 RAs stimulate pancreatic GLP-1 receptors, which increases insulin secretion, delays gastric emptying, and increases satiety. As a class, GLP-1 RAs lower A1c levels and have been associated with reductions in weight and blood pressure and reduced fluctuations in glucose levels, and they have a low risk of hypoglycemia. Exenatide extended release (ER) and dulaglutide monotherapy have shown similar or superior reductions in A1c and weight compared with various oral antidiabetic drugs (OADs). Semaglutide has been shown to reduce both A1c and body weight compared with placebo and, in head-to-head studies versus both exenatide ER and dulaglutide, showed greater reductions in A1c and body weight. Once-weekly GLP-1 RAs have also been evaluated as add-on therapy in the continuum of care for the treatment of T2DM in combination with a variety of background medications, including 1 or more OADs (metformin, sulfonylureas, and/or thiazolidinediones), basal insulin, and prandial insulin. Gastrointestinal adverse events (e.g., nausea, vomiting, and diarrhea) are the most common side effects with once-weekly GLP-1 RAs. Rates of hypoglycemia, and especially major/severe hypoglycemia, are low with once-weekly GLP-1 RAs but, as expected, are higher when used in combination with sulfonylureas or insulin. These once-weekly GLP-1 RAs provide a safe and effective treatment option for patients with T2DM and may offer improved convenience and possibly greater adherence compared with daily GLP-1 RAs. PMID: 30156445 FFT
  7. Yes, but you have to understand that short bowel causes malnourishment by rapid transit and malabsorption. Increasing the surface area and slowing transit will increase the amount of calories absorbed in an SBS patient irrespective of anorectic or thermogenic properties. One of the most common listed side effects of Teduglutide is “change in appetite”. An SBS patient could have a reduced appetite and still gain weight through enhanced absorption. For perspective my wife went from 5’7” and 90lbs to 100lbs over the past 6 months of use but she eats sparingly and gets nausea post-injection.
  8. 90 seconds of searching turns it up as an adjuvant to short-bowel syndrome that reverses weight loss from the SBS. I'm guessing 'no'.
  9. My wife takes Teduglutide which is a GLP-2 peptide. I wonder if it has similar effects.
  10. Amazon will be delivering some today. Not really expecting much since 'research' T3 and/or T4 doesn't do anything for me. The first time I used it (maybe 12 years ago) I lost weight like crazy. After that, it turns me into a hot sleeper at night, but doesn't budge the scale.
  11. Supnut

    SR9011?

    I saw this for sale on a peptide site and couldn't remember any discussions on it. To my surprise, I can't find any threads on it. Did we discuss this by another name or have we overlooked it?
  12. I bet you'd have to find a really edgy doc that you rx this for weight loss, though. I have an upcoming physical, so I might try to walk my guy down this path.
  13. Lancet. 2018 Aug 25;392(10148):637-649. doi: 10.1016/S0140-6736(18)31773-2. Epub 2018 Aug 16. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. O'Neil PM1, Birkenfeld AL2, McGowan B3, Mosenzon O4, Pedersen SD5, Wharton S6, Carson CG7, Jepsen CH7, Kabisch M7, Wilding JPH8. Obesity and Endocrinology Research, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK. Electronic address: j.p.h.wilding@liverpool.ac.uk. Abstract BACKGROUND: Obesity is a major public health issue, and new pharmaceuticals for weight management are needed. Therefore, we evaluated the efficacy and safety of the glucagon-like peptide-1 (GLP-1) analogue semaglutide in comparison with liraglutide and a placebo in promoting weight loss. METHODS: We did a randomised, double-blind, placebo and active controlled, multicentre, dose-ranging, phase 2 trial. The study was done in eight countries involving 71 clinical sites. Eligible participants were adults (≥18 years) without diabetes and with a body-mass index (BMI) of 30 kg/m2 or more. We randomly assigned participants (6:1) to each active treatment group (ie, semaglutide [0·05 mg, 0·1 mg, 0·2 mg, 0·3 mg, or 0·4 mg; initiated at 0·05 mg per day and incrementally escalated every 4 weeks] or liraglutide [3·0 mg; initiated at 0·6 mg per day and escalated by 0·6 mg per week]) or matching placebo group (equal injection volume and escalation schedule to active treatment group) using a block size of 56. All treatment doses were delivered once-daily via subcutaneous injections. Participants and investigators were masked to the assigned study treatment but not the target dose. The primary endpoint was percentage weight loss at week 52. The primary analysis was done using intention-to-treat ANCOVA estimation with missing data derived from the placebo pool. This study is registered with ClinicalTrials.gov, number NCT02453711. FINDINGS: Between Oct 1, 2015, and Feb 11, 2016, 957 individuals were randomly assigned (102-103 participants per active treatment group and 136 in the pooled placebo group). Mean baseline characteristics included age 47 years, bodyweight 111·5 kg, and BMI 39·3 kg/m2. Bodyweight data were available for 891 (93%) of 957 participants at week 52. Estimated mean weight loss was -2·3% for the placebo group versus -6·0% (0·05 mg), -8·6% (0·1 mg), -11·6% (0·2 mg), -11·2% (0·3 mg), and -13·8% (0·4 mg) for the semaglutide groups. All semaglutide groups versus placebo were significant (unadjusted p≤0·0010), and remained significant after adjustment for multiple testing (p≤0·0055). Mean bodyweight reductions for 0·2 mg or more of semaglutide versus liraglutide were all significant (-13·8% to -11·2% vs -7·8%). Estimated weight loss of 10% or more occurred in 10% of participants receiving placebo compared with 37-65% receiving 0·1 mg or more of semaglutide (p<0·0001 vs placebo). All semaglutide doses were generally well tolerated, with no new safety concerns. The most common adverse events were dose-related gastrointestinal symptoms, primarily nausea, as seen previously with GLP-1 receptor agonists. INTERPRETATION: In combination with dietary and physical activity counselling, semaglutide was well tolerated over 52 weeks and showed clinically relevant weight loss compared with placebo at all doses. PMID: 30122305 Weight loss of +10% in a year is hella impressive. This stuff is also now available as an oral formulation.
  14. It's just my insecurities and frustrations trying to rip out of my chest No I guess it was a spasm. There was definitely a bulge in my chest. There are witnesses!
  15. So you boned your way into a mental hernia?
  16. Last week
  17. So last night I was visiting the girl I'm seeing, and in the midst of our time together I felt pain and saw large protrusion around my upper right abdominal wall around my ribs. It was soft. I suspect it was just an aggressive spasm that pulled a rib out, but it could be a hernia. I'm trying to be seen by a doc but the fuckers are taking their time turning around a call. Hopefully it's not a hernia. Either way, this doesn't bode too well for my lifting. Of course this happens now, too.
  18. Bench 45x20 95x10 135x10 185x5 225x3 255x1 285x2x4S 285xAMRAP (x10) 235x10 195x10 145x15 Pec-deck flyes 120x10 130x10 140x10 Reverse pec-deck 110x15 120x10 130x10 140x5, 120x5 Triceps Hell Over 57.5x20 62.5x20 Under 47.5x20 52.5x20 Superset Low cable biceps curl and standing crunch 52.5x10 72.5x15 54x10 77.5x15 59x10 82.5x15 XXX 87.5x15 Seated concentration curl done strict and slow 25x10 30x10 35x10 25x10
  19. Running research: Heel-toe or toe-heel? December 12, 2019 Science News New research from La Trobe University suggests there is no evidence that changing a runner's strike pattern will help prevent injuries or give them a speed boost. In a bid to avoid shin splints, sore knees and other injuries, many runners have adopted a toe-to-heel trend, running on the balls of their feet. This is often encouraged by coaches and health professionals. However, in research out this week in Sports Medicine, La Trobe injury researcher and physiotherapist Dr Christian Barton found there is no evidence to suggest running on the front of your feet reduces injury risk or improves performance. "We analysed 53 studies which looked at the impact of forefoot, rearfoot and flatfoot running patterns on injury, running economy and running biomechanics," senior author of the study, Dr Barton said "Our comprehensive review suggests that telling someone to run on the ball of their foot instead of their heel may make them less efficient, at least in the short term. Additionally, there is no evidence either way on whether running on the balls of your feet reduces injury." Dr Barton said switching your running style shifts the body's loads but doesn't make them disappear. "Running toe-heel might help injuries at the knee, where loads are reduced. However, it may cause injuries to the feet and ankle, where loads are increased," Dr Barton said. "Put simply, when it comes to running style: If it ain't broke, don't fix it." Journal Reference: Laura M. Anderson, Daniel R. Bonanno, Harvi F. Hart, Christian J. Barton. What are the Benefits and Risks Associated with Changing Foot Strike Pattern During Running? A Systematic Review and Meta-analysis of Injury, Running Economy, and Biomechanics. Sports Medicine, 2019
  20. Way way back in the day I used to love Biotest’s T-2 product; paired with MD6 was one of the leanest times of my life and I felt great throughout. I am tempted to give this a try again.
  21. Yes, I know that feeling all too well. Rest up, Oz.
  22. Try getting a chest cold. I've been coughing up a long. But my abs..oh yeah. They're so good.
  1. Load more activity
×
×
  • Create New...